Be Biopharma Stock
HealthTechLooking to sell Be Biopharma stock or options?
Be Biopharma is pioneering B cell medicines designed for applications extending beyond mere cytotoxicity. The company's therapies tackle significant challenges in cell and gene treatments, offering solutions that are durable, reprogrammable, and administrable without harmful conditioning. This innovation empowers healthcare professionals to address diseases such as cancer, autoimmune disorders, and enzyme deficiencies effectively.
Pathway to Cures, RA Capital Management, Atlas Venture, Alta Partners, Bristol-Myers Squibb, ARCH Venture Partners, DC Investment Partners, Takeda Ventures, Longwood Fund.
Collective explained in 2 minutes
Learn how Collective's solutions enable you to manage your risk and maximize your wealth
Our available services for this company
Management Team
Board Members
Be Biopharma’s stock FAQs
Be Biopharma is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize Be Biopharma stock. Depending on Be Biopharma’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange Be Biopharma stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of Be Biopharma stock in two ways. First, Be Biopharma employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your Be Biopharma stock. Note that all transactions in Be Biopharma shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
Be Biopharma stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for Be Biopharma stock. Typically, shares of private companies like Be Biopharma are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Apr 2022, Be Biopharma is reported to have closed an equity financing in which the investors valued the company at $280M. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of Be Biopharma shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because Be Biopharma is not currently publicly traded, it does not have a ticker symbol.
Be Biopharma has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though Be Biopharma is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on Be Biopharma shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.
